StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note published on Wednesday morning. The firm issued a hold rating on the stock.

Tonix Pharmaceuticals Stock Performance

Shares of Tonix Pharmaceuticals stock opened at $0.31 on Wednesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The business’s 50 day moving average price is $0.24 and its 200 day moving average price is $0.36. The company has a market cap of $57.94 million, a price-to-earnings ratio of -0.01 and a beta of 2.02. Tonix Pharmaceuticals has a one year low of $0.12 and a one year high of $12.61.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, research analysts predict that Tonix Pharmaceuticals will post -17.63 EPS for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.